Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method

被引:8
作者
Browning, Marc R. [1 ]
Drexler, Dieter M. [2 ]
Olah, Timothy V. [3 ]
Morgan, Daniel G. [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, Bioanalyt Res, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, Discovery Analyt Sci, Wallingford, CT 06492 USA
[3] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, Bioanalyt Res, Lawrenceville, NJ 08543 USA
关键词
TURBULENT-FLOW CHROMATOGRAPHY; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; SAMPLE ANALYSIS; QUANTITATION; EXTRACTION; PLASMA; VALIDATION;
D O I
10.4155/BIO.10.25
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Bioanalytical support of drug-discovery efforts increasingly requires more complex multiple component analysis, including the bioanalysis of drugs, prodrugs and metabolites. Just as the physiochemical properties of these components may differ widely from each other, optimal LC and MS conditions, including polarity, can also vary greatly among the analytes of interest, thus presenting significant challenges during quantitative LC-MS-based bioanalysis. A single compromised method for the determination of all analytes may sacrifice sensitivity or chromatographic conditions for one analyte in order to achieve adequate results for another. Manually switching between assay conditions to analyze samples under separately optimized conditions for individual compounds can be time consuming. Results: The method presented here addresses the problem of differential analyte optimization using a multiplexed approach for simultaneous quantitative bioanalysis of multiple analytes in the same sample, employing a mixed mode of both turbulent- and laminar-flow chromatography. Conclusion: The approach is illustrated with the quantitation of a lipophilic drug and its hydrophilic phosphate ester prodrug in a biological matrix under individually optimized LC-MS conditions.
引用
收藏
页码:745 / 753
页数:9
相关论文
共 35 条
[1]  
ACKERMANN BL, 2002, AM PHARM REV, V5, P54
[2]  
ACKERMANN BL, 2002, AM PHARM REV, V5, P58
[3]  
ACKERMANN BL, 2002, AM PHARM REV, V5, P60
[4]  
Ayrton J, 1997, RAPID COMMUN MASS SP, V11, P1953, DOI 10.1002/(SICI)1097-0231(199712)11:18<1953::AID-RCM102>3.0.CO
[5]  
2-Z
[6]   Key elements of bioanalytical method validation for small molecules [J].
Bansal, Surendra ;
DeStefano, Anthony .
AAPS JOURNAL, 2007, 9 (01) :E109-E114
[7]   Quantitative-Qualitative Data Acquisition Using a Benchtop Orbitrap Mass Spectrometer [J].
Bateman, Kevin P. ;
Kellmann, Markus ;
Muenster, Helmut ;
Papp, Robert ;
Taylor, Lester .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2009, 20 (08) :1441-1450
[8]  
Bayliss MK, 2000, RAPID COMMUN MASS SP, V14, P2039, DOI 10.1002/1097-0231(20001115)14:21<2039::AID-RCM130>3.0.CO
[9]  
2-2
[10]   Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma [J].
Cui Shuangjin ;
Fang, Feng ;
Ming, Ma ;
Han, Liu ;
Yun, Chen .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 854 (1-2) :143-151